VivoSeq
Other

Proctitis

9

Pipeline Programs↗

4

Active Trials↗

8

Companies Involved↗

Proctitis is an early-stage landscape with 9 programs across 8 companies. The most active players are Jiangsu Topcel-KH Pharmaceutical Co., Ltd., Salix, Bristol-Myers Squibb. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1S

Salix

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2T

Taiwan Bio Therapeutics Inc.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 3Takeda logo

Takeda

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

12 of 13 classified programs — the dominant modality here.

8%ALL OTHERSCell therapy18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed4 · 31%
Unknown status3 · 23%
Not yet recruiting2 · 15%
Terminated2 · 15%
Enrolling by invitation1 · 8%
Recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Umbilical-Cord-Derived Mesenchymal Stem Cells Injection for Chronic Radiation Proctitis
Recruiting·JJiangsu Topcel-KH Pharmaceutical Co., Ltd.·Phase 1/2·NCT06438809·24 enrolled
A Randomized Controlled Trial of Five - Flavor Sophora Flavescens Enteric - Coated Capsules for Radiation - Induced Proctitis After Pelvic Radiotherapy
Not yet recruiting·PPeking University First Hospital·Phase 2·NCT07053761·124 enrolled
Evaluate the Distribution and Dynamic Behavior of Nuclide Labeled TH-SC01 Cells in Vivo in Patients With Radiation Proctitis
Not yet recruiting·JJiangsu Topcel-KH Pharmaceutical Co., Ltd.·Phase 1·NCT06925607·6 enrolled
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Teslanbaicin in Patients With Radiation Proctitis
Enrolling by invitation·TThe First Affiliated Hospital of Xinxiang Medical College·Phase 1/2·NCT06974123·29 enrolled
QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)
Completed·Ferring logoFerring·N/A·NCT02368743·117 enrolled
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis
Completed·TThe University of Western Australia·Phase 4·NCT01418131·21 enrolled
Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis
Completed·—·Phase 2·NCT01966783·320 enrolled
Efficacy of Hyaluronic Acid in Prevention of Acute Radiation Proctitis
Completed·—·Phase 1/2·NCT06469216·44 enrolled
Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis
Terminated·—·Phase 2·NCT00828230·17 enrolled
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Terminated·FForest Laboratories·Phase 3·NCT01016262·119 enrolled
Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis
Unknown status·MMedical University Innsbruck·Phase 3·NCT04335617·200 enrolled
The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis
Unknown status·WWest China Hospital·Phase 2/3·NCT05406882·176 enrolled
Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding
Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT04680195·62 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)